Shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) have earned a consensus recommendation of “Hold” from the fourteen analysts that are covering the company, MarketBeat reports. Three ...
Researchers have been "making great inroads" in precision medicine, and a 15 percent cap on indirect costs could quash the momentum, experts worry.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback